Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

591

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Acne Vulgaris
Interventions
DRUG

Benzoyl peroxide gel

5% benzoyl peroxide in a gel applied topically once a day

DRUG

Clindamycin gel

1% clindamycin phosphate applied topically once a day

DRUG

Tazarotene cream

0.1 % tazarotene in a cream applied topically once a day

DRUG

Vehicle gel

Vehicle gel is an identical gel without the active ingredients

DRUG

Vehicle cream

Vehicle cream is an identical cream without the active ingredients

Trial Locations (16)

17033

MS Hershey Medical Center, Hershey

20721

Callender Center for Clinical Research, Mitchellville

27262

Dermatology Consulting Services, High Point

27599

University of North Carolina Chapel Hill, Chapel Hill

30263

MedaPhase, Inc., Newnan

33134

Dermatology Associates Research, Coral Gables

37072

Rivergate Dermatology & Skin Care Center, Goodlettsville

37922

The Skin Wellness Center, PC, Knoxville

48088

Grekin Skin Institute, Warren

72205

Dermatology Research of Arkansas, Little Rock

75230

Dermatology Treatment & Research Center, Dallas

77056

Suzanne Bruce and Associates, PA, Houston

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

80304

Boulder Medical Center, P.C., Boulder

94538

Center for Dermatology Cosmetic and Laser Surgery, Fremont

95819

Center for Dermatology and Laser Surgery, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY

NCT00713609 - Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne | Biotech Hunter | Biotech Hunter